Edwards Lifesciences Reports Second Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Edwards Lifesciences (EW) PT, Estimates Lifted at Piper Jaffray Amid Solid Q2
July 29, 2015 9:02 AM EDTPiper Jaffray analyst Brooks West reiterated an Overweight rating and boosted estimates and his price target on Edwards Lifesciences (NYSE: EW) to $181.00 (from $170.00) following Q2 results.
West commented, "Edwards reported Q2 revenues of $616.8M, beating our Street high estimate of $615.5M and consensus... More
Edwards Lifesciences (EW) Tops Q2 EPS by 8c; Lifts FY15 Outlook
July 28, 2015 4:38 PM EDTEdwards Lifesciences (NYSE: EW) reported Q2 EPS of $1.13, $0.08 better than the analyst estimate of $1.05. Revenue for the quarter came in at $616.8 million versus the consensus estimate of $604.97 million.
"Strong performance this quarter was boosted by growing global TAVR therapy adoption, with our transcatheter heart... More
